KOSPICosmetics226320

It's Hanbul

₩9,650▼ 2.43%2026-11-18 close
Market Cap
₩211.6B
Turnover
₩100M
Volume
10K
Shares out.
21.9M
PER
12.4×
PBR
0.4×
EPS
₩792
Dividend Yield
2.81%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩275 per share · Prices as of the 2026-11-18 close

01

Report overview

It's Hanbul: Operating profit rises, but Q3 turns to a net loss

It's Hanbul's annual revenue and operating profit rose for three straight years through 2025, and quarterly operating profit has grown for four consecutive quarters, yet the company swung to a KRW 8.27 billion net loss attributable to controlling shareholders in Q3 2026.

  1. 1

    On a filed basis, annual revenue grew from KRW 130.7 billion in 2022 to KRW 153.4 billion in 2025, and the operating margin held at 12.6% in 2024 and 12.5% in 2025.

  2. 2

    Q3 2026 revenue fell 9.8% from the prior quarter to KRW 44.8 billion, while operating profit reached KRW 7.43 billion, the fourth straight quarterly increase; net income attributable to controlling shareholders swung to a KRW 8.27 billion loss.

  3. 3

    Operating cash flow rose from KRW 7.09 billion in 2022 to KRW 28.1 billion in 2025, and total liabilities stood at KRW 29.4 billion at the end of 2025.

  4. 4

    Consolidated earnings depend heavily on the subsidiary NeopharmCO, and the rise of local Chinese brands and tighter regulation are cited as variables for overseas sales.

  5. 5

    The 2026 annual report, the next periodic filing, will show how full-year net income attributable to controlling shareholders settles and whether the Q3 loss was a one-off.

02

Business structure

It's Hanbul is a cosmetics manufacturer and seller founded in 1989, operating across production, R&D, marketing and distribution within one group. It runs its own brands It's Skin and Chasing Rabbit alongside brands at its subsidiary NeopharmCO.

It's Skin is pursuing new product launches and a mass-market campaign for Chasing Rabbit, and is developing digital skin-care features such as an AI-based product recommendation service and virtual makeup simulation. Distribution spans multiple domestic and overseas channels.

Domestic sales in Q1 2025 were KRW 13.6 billion, down 28% from the prior quarter, while overseas and global subsidiary sales rose 30% to KRW 9.3 billion, or 26% of the total. Overseas sales and exports in 2023 were KRW 46.1 billion, roughly flat from the prior year.

The company signed a supplementary supply agreement for China worth KRW 53.7 billion with a Chinese partner. In November 2023 it sold its domestic Eumseong production plant to NeopharmCO for KRW 17.2 billion, and NeopharmCO has since handled production for It's Hanbul products. Headcount fell from 163 in 2022 to 93 in 2025.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩37.8B₩4.8B12.8%
2025Q4₩42B₩4.9B11.6%
2026Q1₩42.7B₩6.8B16.0%
2026Q2₩49.7B₩7.3B14.8%
2026Q3₩44.8B₩7.4B16.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩130.7B₩4.8B-₩6.8B3.7%−1.8%6.6%
2023₩139.2B₩8.1B₩3.4B5.8%0.9%6.8%
2024₩142.4B₩17.9B₩16.5B12.6%4.4%5.9%
2025₩153.4B₩19.2B₩16.7B12.5%4.3%5.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 130.7 billion in 2022 to KRW 139.2 billion in 2023 (up 6.5% year on year), KRW 142.4 billion in 2024 (up 2.3%) and KRW 153.4 billion in 2025 (up 7.7%), growing for three consecutive years from 2023 through 2025, with 2025 the largest year of the 2022 to 2025 period.

Operating profit went from KRW 4.81 billion in 2022 to KRW 8.05 billion in 2023 (up 67.5%), KRW 17.9 billion in 2024 (up 122.0%) and KRW 19.2 billion in 2025 (up 7.4%).

The operating margin climbed from 3.7% in 2022 and 5.8% in 2023 to 12.6% in 2024, then held at 12.5% in 2025, so the margin gains concentrated in 2024 while 2025 kept margins steady as sales grew.

Net income attributable to controlling shareholders moved from a net loss of KRW 6.82 billion in 2022 to a profit of KRW 3.4 billion in 2023, KRW 16.5 billion in 2024 (up 386.2%) and KRW 16.7 billion in 2025 (up 1.3%), growing for two consecutive years from 2024 through 2025.

Net income including non-controlling interests was KRW 3.31 billion, KRW 17.4 billion, KRW 29.7 billion and KRW 32.6 billion over the same years, above the controlling-shareholder figure, with the gap reflecting the share of minority holders in consolidated subsidiaries.

At the end of 2025, total equity was KRW 506.3 billion, of which KRW 389.7 billion belonged to controlling shareholders, and the debt ratio fell from 6.6% in 2022 to 5.8% in 2025. Operating cash flow rose from KRW 7.09 billion in 2022 to KRW 28.1 billion in 2025.

Quarterly revenue went from KRW 37.8 billion in Q3 2025 to KRW 42 billion in Q4 (up 11.3% from the prior quarter), KRW 42.7 billion in Q1 2026 (up 1.5%) and KRW 49.7 billion in Q2 2026 (up 16.4%), before falling to KRW 44.8 billion in Q3 2026 (down 9.8% from the prior quarter, up 18.6% year on year).

Quarterly operating profit ran KRW 4.82 billion, KRW 4.87 billion, KRW 6.83 billion, KRW 7.33 billion and KRW 7.43 billion from Q3 2025 to Q3 2026, rising for four consecutive quarters from Q4 2025 through Q3 2026.

Net income attributable to controlling shareholders was KRW 7.68 billion in Q3 2025, KRW 6.6 billion in Q4, KRW 9.41 billion in Q1 2026 and KRW 9.63 billion in Q2, before a KRW 8.27 billion net loss in Q3 2026 turned the quarter into a loss. The sum for the last four quarters was KRW 17.4 billion.

Because operating profit rose while controlling-shareholder earnings turned negative, the items between operating profit and net income, including non-operating items and income tax, are the next points to check.

05

Industry analysis

Within the cosmetics sector, It's Hanbul is a mid-sized company that combines its own brands with in-house manufacturing capability through subsidiaries. In China, the rapid growth of local Chinese cosmetics brands and tighter regulation have weighed on China-bound sales.

A 2022 analysis cited fewer foreign tourists visiting Korea as a drag on duty-free and China-related sales. Offline domestic cosmetics growth slowed after masks became routine, and competition in online channels intensified.

The company has responded by expanding its own online mall and home-shopping channels and by pursuing markets outside China. Consumer interest has shifted toward derma, vegan and clean beauty, and the company has stepped up product development and marketing in those areas.

Its cumulative 2025 nine-month sales and operating profit rose from the prior year, which suggests the product strategy contributed.

Peers include large brand companies such as Amorepacific and LG H&H, contract manufacturers such as Cosmax and Kolmar Korea, and online-driven brand companies such as APR and CLIO Cosmetics.

It's Hanbul is smaller than most of these, and how that gap shows up in channel bargaining power and overseas expansion speed is the key comparison point.

06

Outlook

The main forward-looking fact is a supplementary China supply agreement worth KRW 53.7 billion, whose execution pace will show up in overseas sales. Operating profit rose slightly in Q3 2026 even as revenue declined from the prior quarter, which points to shifts in product mix and cost structure.

The company made a voluntary disclosure of a corporate value-up plan on March 27, 2026, and on August 14, 2026 it filed a correction to the business report for 2025. Whether the correction affects consolidated figures should be checked against the original correction filing.

The half-year report for 2026 was filed on the same day, so the first-half 2026 figures are now fixed in filings. Because the subsidiary NeopharmCO drives much of consolidated profit, its results and year-end dividend will be a key variable for upcoming quarters.

Q4 2026 results have not yet appeared in a periodic report, and the quarterly trend will only be fixed once preliminary results and the annual report are out.

The 2026 annual report is the next periodic filing, and its full-year controlling-shareholder net income and the composition of non-operating items will set the reference for judging 2026 as a whole.

07

Valuation

PER
12.4×
PBR
0.4×
ROE
4.5%
EPS
₩792
BPS
₩22,378
Dividend per share
₩275

The share price trades well below book value per share, with the price-to-book ratio under 1x. Controlling shareholders' equity makes up most of total equity, and total liabilities are small, so the balance-sheet base is solid.

The price sitting below net asset value is tied to the fact that earnings power is limited relative to the asset base.

The sum of net income attributable to controlling shareholders over the last four quarters was KRW 17.4 billion, but the Q3 2026 loss means earnings-based multiples can swing sharply with each quarter's result.

The earnings recovery in 2024 and 2025 represents a turn away from earlier losses, while the Q3 2026 result shows whether that trend holds. Dividends depend on the year-end distribution from the subsidiary NeopharmCO, so they are shaped more by that subsidiary's dividend policy and results than by consolidated profit.

Compared with large industry peers, the size gap is wide, which limits direct comparison on the same multiple basis. The next reference point for reading these multiples is how controlling-shareholder net income is settled in the 2026 annual report and the Q1 2027 quarterly report.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Recovery in operating profit

Operating profit grew from KRW 4.81 billion in 2022 to KRW 19.2 billion in 2025, with the operating margin at 12.6% in 2024 and 12.5% in 2025. Quarterly operating profit rose to KRW 6.83 billion, KRW 7.33 billion and KRW 7.43 billion in 2026, a fourth consecutive quarterly increase.

Operating profit also rose in Q2 2026 when revenue grew, showing sales growth carried through to profit in that period.

Cash generation and financial capacity

The debt ratio fell from 6.6% in 2022 to 5.8% in 2025, and total liabilities of KRW 29.4 billion are small against total equity of KRW 506.3 billion at the end of 2025. The light balance sheet means borrowing pressure remains limited even if the operating environment weakens.

Subsidiary structure and price relative to book value

The subsidiary NeopharmCO took over the Eumseong plant and handles production, and It's Hanbul receives consolidated earnings and year-end dividends from it. The share price sits below book value per share, which supports a view that the price is modest relative to assets. That view depends on whether earnings power against the asset base recovers in the 2026 annual report.

09

Bear factors

Controlling-shareholder net loss in Q3

Net income attributable to controlling shareholders swung to a KRW 8.27 billion loss in Q3 2026, from KRW 9.63 billion of profit in the prior quarter and KRW 7.68 billion a year earlier. Revenue fell 9.8% from the prior quarter to KRW 44.8 billion.

Operating profit rose to KRW 7.43 billion, but results deteriorated below the operating line, so the items driving the swing still need to be identified.

Structural pressure from China and channels

Analyses point to rapid growth of local Chinese cosmetics brands and tighter regulation weighing on China-bound sales. A 2022 analysis noted that fewer foreign visitors to Korea reduced duty-free and China-related sales.

Offline domestic growth has slowed while online competition has intensified, adding channel and promotional costs.

Dependence on a subsidiary and standalone losses

Standalone operating profit posted losses continuously from Q3 2024 through Q3 2025. Commentary has pointed to the subsidiary NeopharmCO as the main reason consolidated profit held up.

Because the group relies on subsidiary results and dividends, changes in that subsidiary's sector conditions or dividend policy would flow through to the parent's earnings.

10

Risk factors

Quarterly earnings volatility

Revenue fell from KRW 49.7 billion in Q2 2026 to KRW 44.8 billion in Q3, a 9.8% quarter-on-quarter decline, while controlling-shareholder earnings flipped from profit to loss over the same stretch.

Even with four consecutive quarters of higher operating profit, net income can swing sharply each quarter, making it hard to read the trend from one result. Whether non-operating items and income tax are amplifying the swings needs to be checked.

China regulation and competition

Tighter Chinese regulation and the rise of local brands could increase volatility in China-bound sales. The KRW 53.7 billion supplementary agreement is large, so its execution could be affected by trading terms or regulatory changes.

The real size of this risk becomes clear only when execution progress and China-related sales are read together.

Filing corrections and subsidiary dependence

A correction to the 2025 business report was filed on August 14, 2026. The content of the correction should be checked against the original filing, including whether consolidated figures changed.

Because consolidated earnings rely on the subsidiary NeopharmCO's results and dividends, changes at that subsidiary feed directly into the parent's reported figures.

11

What to watch next

  1. Early February 2027 (estimated from last year's Q4 release timing)

    Preliminary Q4 and full-year 2026 results. Check whether operating profit continues its four-quarter rise and what non-operating items drove the Q3 loss attributable to controlling shareholders.

  2. Late March 2027 (statutory filing deadline)

    Filing of the 2026 annual report. Check how full-year controlling-shareholder net income, total net income and the subsidiary contribution are settled in filed figures.

  3. Mid-May 2027 (estimated from last year's Q1 report timing)

    Q1 2027 quarterly report. Check whether controlling-shareholder net income returns to profit and how China-related and domestic sales trend quarter by quarter.

  4. During the first half of 2027

    Execution progress of the KRW 53.7 billion China supplementary supply agreement and whether it shows up in overseas sales mix and China-related sales.

12

Overall view

It's Hanbul's revenue and operating profit recovered from 2022 through 2025, ending 2025 at KRW 153.4 billion and KRW 19.2 billion, with the operating margin holding at a high level of 12.6% in 2024 and 12.5% in 2025.

Net income attributable to controlling shareholders turned to profit in 2023 and grew for two consecutive years in 2024 and 2025. In 2026, quarterly operating profit rose for four straight quarters, but Q3 brought a KRW 8.27 billion net loss attributable to controlling shareholders.

Points cited on the upside include the recovery in operating profit, rising operating cash flow and a low debt ratio. Points on the downside include the Q3 swing to a loss, pressure from China regulation and channels, and reliance on subsidiary NeopharmCO's results and dividends.

On valuation, the share price sits below book value per share, but earnings-based multiples can move sharply with each quarter's result.

The 2026 annual report, the next periodic filing, will settle full-year controlling-shareholder net income and the mix of non-operating items, and that will be the reference for reading the Q3 loss.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. jobkorea.co.kr
  3. vegannews.co.kr
  4. comp.fnguide.com
  5. beautynury.com
  6. beautynury.com
  7. pharm.edaily.co.kr
  8. jobkorea.co.kr
  9. consumernews.co.kr
  10. goinsider.kr
  11. beautynury.com
  12. investing.com
  13. saramin.co.kr
  14. ilyosisa.co.kr
  15. judal.co.kr
  16. judal.co.kr
  17. judal.co.kr
  18. judal.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis